FGFR-TKI Resistance in Cancer: Current Status and Perspectives

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2021 Feb 11

PMID 33568192

Citations 52

Authors

Sitong Yue

Yukun Li

Xiaojuan Chen

Juan Wang

Meixiang Li

Yongheng Chen

Daichao Wu

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation, differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase inhibitors (TKI) has achieved great success in tumor-targeted therapy. However, resistance to FGFR-TKI has become a concern. Here, we review the mechanisms of FGFR-TKI resistance in cancer, including gatekeeper mutations, alternative signaling pathway activation, lysosome-mediated TKI sequestration, and gene fusion. In addition, we summarize strategies to overcome resistance, including developing covalent inhibitors, developing dual-target inhibitors, adopting combination therapy, and targeting lysosomes, which will facilitate the transition to precision medicine and individualized treatment.

Citing Articles

Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research.

Bou Antoun N, Afshan Mahmood H, Walker A, Modjtahedi H, Grose R, Chioni A Int J Mol Sci. 2025; 26(5).

PMID: 40076427 PMC: 11898767. DOI: 10.3390/ijms26051799.

Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma.

Kim Y, Song J, Kim N, Sim T RSC Med Chem. 2025; .

PMID: 39925737 PMC: 11800140. DOI: 10.1039/d4md00881b.

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives.

Luo D, Liu Y, Lu Z, Huang L Mol Med. 2025; 31(1):52.

PMID: 39923010 PMC: 11806620. DOI: 10.1186/s10020-025-01075-y.

Landscape of targeted therapies for lung squamous cell carcinoma.

Chen Q, Zheng X, Cheng W, Li J Front Oncol. 2024; 14:1467898.

PMID: 39544292 PMC: 11560903. DOI: 10.3389/fonc.2024.1467898.

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.

Kwon W J Korean Med Sci. 2024; 39(43):e320.

PMID: 39536791 PMC: 11557252. DOI: 10.3346/jkms.2024.39.e320.

References

Kim Y, Kim Y, Lee S, Yang H, Kim S . Personalized Prediction of Acquired Resistance to EGFR-Targeted Inhibitors Using a Pathway-Based Machine Learning Approach. Cancers (Basel). 2019; 11(1). PMC: 6357167. DOI: 10.3390/cancers11010045. View

Ryan M, Sohl C, Luo B, Anderson K . The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT. Mol Cancer Res. 2018; 17(2):532-543. PMC: 6647014. DOI: 10.1158/1541-7786.MCR-18-0429. View

Chen C, Changou C, Hsieh T, Lee Y, Chu C, Hsu K . Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer. Clin Cancer Res. 2017; 24(5):1176-1189. DOI: 10.1158/1078-0432.CCR-17-2066. View

Gnatenko D, Kopantzev E, Sverdlov E . [Fibroblast growth factors and their effects in pancreas organogenesis]. Biomed Khim. 2017; 63(3):211-218. DOI: 10.18097/PBMC20176303211. View

Van Cutsem E, Bang Y, Mansoor W, Petty R, Chao Y, Cunningham D . A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017; 28(6):1316-1324. DOI: 10.1093/annonc/mdx107. View

Chen C, Hsieh T, Lin Y, Liu Y, Liou J, Yen Y . Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells. Cancers (Basel). 2019; 11(9). PMC: 6770340. DOI: 10.3390/cancers11091345. View

Zhitomirsky B, Yunaev A, Kreiserman R, Kaplan A, Stark M, Assaraf Y . Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity. Cell Death Dis. 2018; 9(12):1191. PMC: 6294013. DOI: 10.1038/s41419-018-1227-0. View

Montazeri K, Bellmunt J . Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev Clin Pharmacol. 2019; 13(1):1-6. DOI: 10.1080/17512433.2020.1702025. View

Datta J, Damodaran S, Parks H, Ocrainiciuc C, Miya J, Yu L . Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Mol Cancer Ther. 2017; 16(4):614-624. PMC: 5539948. DOI: 10.1158/1535-7163.MCT-15-1010. View

10.

Krook M, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey K . Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Mol Cancer Ther. 2020; 19(3):847-857. PMC: 7359896. DOI: 10.1158/1535-7163.MCT-19-0631. View

11.

Englinger B, Kallus S, Senkiv J, Heilos D, Gabler L, van Schoonhoven S . Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. J Exp Clin Cancer Res. 2017; 36(1):122. PMC: 5590147. DOI: 10.1186/s13046-017-0592-3. View

12.

Sase H, Nakanishi Y, Aida S, Horiguchi-Takei K, Akiyama N, Fujii T . Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in -Amplified Gastric Cancer. Mol Cancer Ther. 2018; 17(10):2217-2225. DOI: 10.1158/1535-7163.MCT-17-1022. View

13.

Cowell J, Qin H, Hu T, Wu Q, Bhole A, Ren M . Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. Int J Cancer. 2017; 141(9):1822-1829. PMC: 5850950. DOI: 10.1002/ijc.30848. View

14.

Harbinski F, Craig V, Sanghavi S, Jeffery D, Liu L, Sheppard K . Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2012; 2(10):948-59. DOI: 10.1158/2159-8290.CD-12-0237. View

15.

Babina I, Turner N . Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017; 17(5):318-332. DOI: 10.1038/nrc.2017.8. View

16.

Maroun C, Rowlands T . The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther. 2014; 142(3):316-38. DOI: 10.1016/j.pharmthera.2013.12.014. View

17.

Ware K, Hinz T, Kleczko E, Singleton K, Marek L, Helfrich B . A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013; 2:e39. PMC: 3641357. DOI: 10.1038/oncsis.2013.4. View

18.

Zhou Y, Wu C, Lu G, Hu Z, Chen Q, Du X . FGF/FGFR signaling pathway involved resistance in various cancer types. J Cancer. 2020; 11(8):2000-2007. PMC: 7052940. DOI: 10.7150/jca.40531. View

19.

Kazmi F, Hensley T, Pope C, Funk R, Loewen G, Buckley D . Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos. 2013; 41(4):897-905. PMC: 3608459. DOI: 10.1124/dmd.112.050054. View

20.

Malchers F, Ercanoglu M, Schutte D, Castiglione R, Tischler V, Michels S . Mechanisms of Primary Drug Resistance in -Amplified Lung Cancer. Clin Cancer Res. 2017; 23(18):5527-5536. DOI: 10.1158/1078-0432.CCR-17-0478. View